<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594656</url>
  </required_header>
  <id_info>
    <org_study_id>2017YFC1310202</org_study_id>
    <nct_id>NCT03594656</nct_id>
  </id_info>
  <brief_title>Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease</brief_title>
  <official_title>Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lingzhi(Ganoderma) is widely used in traditional Chinese medicine. Previous studies indicated
      that Lingzhi was safe, well tolorated, and improved symptoms as an add-on therapy to levodopa
      in early Parkinson's disease(PD) patients. Here the investigators design a multicenter,
      randomized, double-blind, placebo-controlled, delayed-start trial to evaluate the effects of
      Lingzhi on modifying disease progression in untreated PD patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in UPDRS Part III subscores</measure>
    <time_frame>72 weeks</time_frame>
    <description>Compare changes in UPDRS part III scores from baseline to week 72 between early-start group and delayed-start group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Schwab-England scores</measure>
    <time_frame>72 weeks</time_frame>
    <description>Compare changes in Schwab-England scores from baseline to week 72 between early-start group and delayed-start group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratios of subjects in need of additional antiparkinsonian drugs</measure>
    <time_frame>72 weeks</time_frame>
    <description>Compare ratios of subjects in need of additional antiparkinsonian drugs during the 72 week period between early-start group and delayed-start group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in ADAS-COG scores</measure>
    <time_frame>72 weeks</time_frame>
    <description>Compare changes in ADAS-COG scores from baseline to week 72 between early-start group and delayed-start group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Early-start Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed-start Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganoderma</intervention_name>
    <description>0.8g twice daily</description>
    <arm_group_label>Delayed-start Group</arm_group_label>
    <arm_group_label>Early-start Group</arm_group_label>
    <other_name>Lingzhi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>0.8g twice daily</description>
    <arm_group_label>Delayed-start Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meeting the criteria for &quot;Probable Parkinson's disease&quot; according to 2015 MDS Clinical
             Diagnostic Criteria for Parkinson's Disease

          -  Aged 30-80 years

          -  Hoehn-Yahr Stageâ‰¤2

          -  UPDRS Part III subscores ranging from 10 to 30 points

          -  Disease duration of 5 years or less

          -  Untreated with antiparkinsonian drugs for at least two weeks preceding the trial

          -  Willing to sign the written informed consent

        Exclusion Criteria:

          -  Atypical or secondary parkinsonism

          -  With psychiatric symptoms or a history of psychiatric diseases

          -  With cognitive impairment(MMSE score&lt;24)

          -  Major liver or kidney dysfunction

          -  Participating in other clinical trials within 3 months preceding the current trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erhe Xu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital of Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erhe Xu, M.D.</last_name>
    <phone>010-83198677</phone>
    <email>xuerhe@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital of Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erhe Xu, M.D.</last_name>
      <phone>010-83198677</phone>
      <email>xuerhe@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>May 26, 2019</last_update_submitted>
  <last_update_submitted_qc>May 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Lingzhi</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

